NEOGENOMICS INC — Director's Dealing 2022

Mar 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2022-03-01

Reporting Person: Mallon Mark (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-01	Common Stock	A	142457	—	Acquired	368051	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-01	Stock Option (Right to Buy)	$21.41	A	347777	Acquired	2029-03-01	Common Stock (347777.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$49.34	2028-04-19	Common Stock (151016.0)	151016	Direct

Footnotes

F1: On March 1, 2022, Mr. Mallon was granted 142,457 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.

F2: On April 19, 2021, Mr. Mallon was granted 151,016 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F3: On March 1, 2022, Mr. Mallon was granted 347,777 stock options. These options vest ratably over the first four anniversary dates of the grant date.